rheumatoid arthritis

Showing 15 posts of 66 posts found.

Orencia image

BMS backs rheumatoid arthritis prevention trial

March 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis

Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …

Abbvie image

AbbVie highlights treatment adherence

June 12, 2014
Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis

Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …

janssen image

Janssen abandons Simponi application

May 23, 2014
Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis

Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …

Pfizer’s Xeljanz rejected in Europe

April 28, 2013
Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis

Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …


MedImmune signs China deal

September 11, 2012
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China, MedImmune, WuXi, emerging markets, rheumatoid arthritis

MedImmune has sealed a joint venture with Shanghai-based WuXi AppTec to develop a novel biologic for autoimmune and inflammatory diseases …

Pfizer’s RA drug on course for approval

May 10, 2012
Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib

An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …

NICE says no to BMS for second-line Orencia

August 25, 2011
Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis

In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis

July 13, 2011
Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab

Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …


Deaths reported in Pfizer arthritis trial

April 26, 2011
Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …


Phase III boost for Pfizer’s oral arthritis drug

April 18, 2011
Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …

Abbott's Humira (adalimumab)

Abbott wins $1.7bn Humira case

February 24, 2011
Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis

Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …

Solid results for AstraZeneca’s oral RA drug

September 23, 2010
Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis

AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …

NICE updates guidance for arthritis treatments

August 26, 2010
Sales and Marketing NICE, Roche, rheumatoid arthritis

Five new drugs for rheumatoid arthritis have been given the thumbs up by NICE as second line treatment. Roche’s MabThera, …

NICE re-thinks arthritis guidance

June 25, 2010
Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis

NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …

Latest content